Aerie Pharmaceuticals convened a group of expert thought leaders in the diagnosis and management of glaucoma to share their insights and experience with Rhopressa^® and Rocklatan^®. Using case studies of patients in their practices as examples, these thought leaders covered topics such as rationale for treatment, efficacy and safety outcomes, ideal candidates for therapy, and managing patient expectations.

INDICATIONS AND DOSAGE FOR ROCKLATAN^® AND RHOPRESSA^®

Indications and Usage: Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa^® (netarsudil ophthalmic solution) 0.02% are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration: The recommended dosage for Rocklatan^® and Rhopressa^® is one drop into the affected eye(s) once daily in the evening.

If Rocklatan^® or Rhopressa^® are to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION FOR RHOPRESSA

CONTRAINDICATIONS
None.

WARNINGS AND PRECAUTIONS

Bacterial Keratitis
There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Please click below for additional Important Safety Information

4301 Emperor Blvd., Suite 400 | Durham, NC 27703 | 919-237-5300